BRPI0908541B8 - uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas - Google Patents

uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas

Info

Publication number
BRPI0908541B8
BRPI0908541B8 BRPI0908541A BRPI0908541A BRPI0908541B8 BR PI0908541 B8 BRPI0908541 B8 BR PI0908541B8 BR PI0908541 A BRPI0908541 A BR PI0908541A BR PI0908541 A BRPI0908541 A BR PI0908541A BR PI0908541 B8 BRPI0908541 B8 BR PI0908541B8
Authority
BR
Brazil
Prior art keywords
fraction
immune responses
adaptive immune
panax quinquefolius
innate
Prior art date
Application number
BRPI0908541A
Other languages
English (en)
Inventor
J Adamko Darryl
Shan Jacqueline
l rosenthal Kenneth
Sutherland Sharla
Wu Yingqi
Original Assignee
Afexa Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afexa Life Sciences Inc filed Critical Afexa Life Sciences Inc
Publication of BRPI0908541A2 publication Critical patent/BRPI0908541A2/pt
Publication of BRPI0908541B1 publication Critical patent/BRPI0908541B1/pt
Publication of BRPI0908541B8 publication Critical patent/BRPI0908541B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ativação de respostas imunes inatas e adaptativas por um extrato de ginseng. a presente invenção refere-se a frações de ginseng e a métodos para ativar respostas imunes inatas e adaptativas para prevenir, tratar ou melhorar uma condição em um individuo, administrando ao individuo uma quantidade eficaz de uma fracão de ginseng, uma composição farmacêutica que compreende a fração em combinação com outro medicamento ou com um ou mais veículos farmaceuticamente aceitáveis, ou um item alimentício que compreende a fração. a fração pode ser fabricada a partir de panax quinquefolius ou pode ser selecionada entre cvt-e002, pq2, e pq223 e frações purificadas a partir de cvt-e002, pq2, e pq223.
BRPI0908541A 2008-02-29 2009-02-27 uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas BRPI0908541B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6435408P 2008-02-29 2008-02-29
US61/064,354 2008-02-29
PCT/IB2009/000379 WO2009106975A2 (en) 2008-02-29 2009-02-27 Activation of innate and adaptive immune responses by a ginseng extract

Publications (3)

Publication Number Publication Date
BRPI0908541A2 BRPI0908541A2 (pt) 2019-08-27
BRPI0908541B1 BRPI0908541B1 (pt) 2021-05-11
BRPI0908541B8 true BRPI0908541B8 (pt) 2021-05-25

Family

ID=41016524

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908541A BRPI0908541B8 (pt) 2008-02-29 2009-02-27 uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas

Country Status (15)

Country Link
US (2) US20110086052A1 (pt)
EP (1) EP2268295B1 (pt)
JP (1) JP5879037B2 (pt)
KR (1) KR101664871B1 (pt)
CN (1) CN102014941B (pt)
AU (1) AU2009219793B2 (pt)
BR (1) BRPI0908541B8 (pt)
CA (1) CA2716366C (pt)
ES (1) ES2539532T3 (pt)
MX (1) MX2010009479A (pt)
MY (1) MY158195A (pt)
NZ (1) NZ587615A (pt)
PL (1) PL2268295T3 (pt)
SG (1) SG188833A1 (pt)
WO (1) WO2009106975A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622982A (zh) * 2013-10-24 2014-03-12 浙江大学 人参皂甙Rg1在制备抗内毒素作用于Toll样受体4药物上的应用
KR101677855B1 (ko) * 2014-08-08 2016-11-21 중앙대학교 산학협력단 자일리톨을 유효성분으로 함유하는 호흡기 세포융합 바이러스 감염증 예방 또는 치료용 조성물
JP6824404B2 (ja) 2016-07-29 2021-02-03 ナチュラル ヘルスケア カンパニー リミテッドＮａｔｕｒａｌ Ｈｅａｌｔｈｃａｒｅ Ｃｏ．，Ｌｔｄ． 粘膜用抗インフルエンザウイルス組成物
KR101837691B1 (ko) * 2016-08-12 2018-03-14 한국한의학연구원 삼칠근 추출물을 함유하는 항바이러스용 조성물
KR101940042B1 (ko) 2017-05-11 2019-01-21 주식회사 케이티앤지 곰보배추 및 홍삼으로 구성된 조합 추출물을 유효성분으로 함유하는 호흡기염증 질환의 예방 및 치료용 조성물
WO2019212203A1 (ko) * 2018-05-02 2019-11-07 ㈜아모레퍼시픽 인삼열매 다당체를 포함하는 인플루엔자 바이러스 감염 예방 또는 억제용 조성물
KR102131043B1 (ko) * 2018-05-02 2020-07-08 (주)아모레퍼시픽 인삼열매 다당체를 포함하는 인플루엔자 바이러스 감염 예방 또는 억제용 조성물
EP3973974A4 (en) * 2019-05-20 2023-05-10 CJ Cheiljedang Corporation COMPOSITION TO INCREASE BIOAVAILABILITY AND PROMOTE ABSORPTION OF GINSENOSIDES IN BLACK GINSENG EXTRACT
US20230181665A1 (en) * 2020-03-20 2023-06-15 Novel Concepts Medical Ltd Treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
RU2738719C1 (ru) * 2020-03-26 2020-12-15 Владислав Николаевич Ласкавый Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с
KR102326439B1 (ko) * 2020-04-20 2021-11-16 주식회사 네이처센스 인삼을 포함하는 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물
CA3202289A1 (en) * 2020-12-15 2022-06-23 Jacqueline J. Shan American ginseng root fractions, processes of their preparation and uses thereof
WO2023008981A1 (ko) * 2021-07-30 2023-02-02 경희대학교 산학협력단 항바이러스 조성물 및 이의 이용

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156A (en) 1849-03-10 Stove foe heating apartments
EP0030444B1 (en) 1979-12-03 1985-01-30 Kitasato Kenkyusho A process for preparing substances having interferon inducing activity
JPS6118722A (ja) 1984-07-05 1986-01-27 Wakunaga Seiyaku Kk 生体防御能亢進剤
SE452776B (sv) 1986-04-02 1987-12-14 Johansson Hanna Maria E Forfarande for framstellning av oligosackarider
JPH0643327B2 (ja) 1987-03-27 1994-06-08 株式会社ツムラ 免疫賦活剤
JPH0245499A (ja) 1988-08-06 1990-02-15 Wakunaga Pharmaceut Co Ltd オタネニンジン糖タンパク質およびその用途
JPH0245501A (ja) 1988-08-06 1990-02-15 Wakunaga Pharmaceut Co Ltd 竹節ニンジン多糖およびその用途
JPH05317041A (ja) 1991-06-05 1993-12-03 Nippon Oil Co Ltd 動物細胞増殖促進剤及び無血清培地
CN1088448A (zh) 1992-12-25 1994-06-29 彭德赐 西洋参多糖营养液和西洋参多糖胶囊及其制备方法
US6083932A (en) * 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) * 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
US6432454B1 (en) 1997-12-12 2002-08-13 C. V. Technologies, Inc. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
US8039027B1 (en) 1999-02-25 2011-10-18 Fx Life Sciences Ag Treatment of autoimmune diseases with American ginseng extract
US6555527B1 (en) 1999-08-27 2003-04-29 Korea Atomic Energy Research Institute Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng
JP2002017299A (ja) * 2000-07-10 2002-01-22 Rasheru Seiyaku Kk 健康食品
US20050130231A1 (en) 2001-12-21 2005-06-16 Yuping Deng Method for analyzing effects of medical agents
AU2003202159A1 (en) * 2002-04-08 2003-10-27 Ginseng Science Inc. Extract of processed panax genus plant, the preparation method thereof, and compositions containing the same
KR100555652B1 (ko) * 2002-04-08 2006-11-10 주식회사 진생사이언스 약효가 증강된 파낙스속 식물의 가공 추출물, 그 제조방법및 그를 함유하는 암 및 알러지 질환의 예방 및 치료를위한 조성물
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
US20050287230A1 (en) 2004-06-25 2005-12-29 Jeffrey Young Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof
ATE483366T1 (de) * 2005-11-14 2010-10-15 Unilever Nv Essbares produkt, das ginseng-polysaccharide und gesunde bakterien enthält
US20090047405A1 (en) * 2007-08-16 2009-02-19 Conopco, Inc., D/B/A Unilever Food composition with therapeutic agents

Also Published As

Publication number Publication date
KR20100124304A (ko) 2010-11-26
AU2009219793B2 (en) 2013-09-26
SG188833A1 (en) 2013-04-30
US20110086052A1 (en) 2011-04-14
KR101664871B1 (ko) 2016-10-11
JP2011513294A (ja) 2011-04-28
EP2268295A4 (en) 2012-03-28
ES2539532T3 (es) 2015-07-01
PL2268295T3 (pl) 2015-08-31
EP2268295B1 (en) 2015-03-25
EP2268295A2 (en) 2011-01-05
US20130295205A1 (en) 2013-11-07
MY158195A (en) 2016-09-15
JP5879037B2 (ja) 2016-03-08
US9050313B2 (en) 2015-06-09
CA2716366A1 (en) 2009-09-03
CN102014941A (zh) 2011-04-13
CN102014941B (zh) 2013-11-06
BRPI0908541A2 (pt) 2019-08-27
WO2009106975A3 (en) 2009-10-29
AU2009219793A1 (en) 2009-09-03
NZ587615A (en) 2012-10-26
BRPI0908541B1 (pt) 2021-05-11
CA2716366C (en) 2018-02-27
WO2009106975A2 (en) 2009-09-03
MX2010009479A (es) 2010-12-07

Similar Documents

Publication Publication Date Title
MY158195A (en) Activation of innate and adaptive immune responses by a ginseng extract
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112013000537A2 (pt) composição aquosa contendo bromexina
CL2013001433A1 (es) Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones.
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
EP4678242A3 (en) Pharmaceutical composition, methods for treating and uses thereof
ECSP13012379A (es) Pirimidinas y triazinas condensadas y su uso
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
BR112015022306A2 (pt) adoçante aperfeiçoado
BR112014030282A2 (pt) métodos de tratamento de excesso de peso e obesidade
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
BRPI0822069B8 (pt) método para preparação de um extrato de fruta de cardo leiteiro
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112016007487A2 (pt) composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
BR112013003471A2 (pt) solução de testosterona, e, método para tratar deficiência de testosterona
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
BR112013028285A2 (pt) indução de il-12 usando imunoterapia
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF